Results 191 to 200 of about 267,025 (304)

Advancements in Inorganic Chiral Nanomaterials for Anti‐Tumor Immunotherapy

Cancer Science, EarlyView.
Schematic illustration of how inorganic chiral nanomaterials enhance immune activation to promote tumor cell elimination through targeted delivery, immunogenic cell death, and immune microenvironment modulation. ABSTRACT While the past decade has witnessed unprecedented technological advancements, cancer remains a major health threat, with conventional
Siyu Chen, Qian Tang, Xiqian Chen, Yinghao Liang, Jin Qiu, Yongmei Liao, Changqiang Li, Hongru Yu, Fang Xie, Zongjunlin Liu   +9 more
wiley   +1 more source

Drivers of bat researchers’ intent to adopt field hygiene practices

Conservation Biology, EarlyView.
Abstract Infectious disease is a growing threat to wildlife, with zoonotic transmission most likely at the human–wildlife interface. One underappreciated activity at this interface is fieldwork with wild animals, but associated risks can be mitigated through field hygiene (FH) practices, such as using personal protective equipment and other appropriate
Joanna L. Coleman, Ewan A. Macdonald, Abigail L. Rutrough, Tanja M. Straka, Todd D. Little, Zachary Stickley, Tigga Kingston   +6 more
wiley   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Effectiveness of Influenza Vaccine in Wuhan, China During the 2024-2025 Season: A Test-Negative Case-Control Study. [PDF]

Vaccines (Basel)
Zhang P, Yang X, Chen B.
europepmc   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Covid-19 and influenza vaccine hesitancy insights from France, Italy and Hungary: A mixed-methods study. [PDF]

Hum Vaccin Immunother
Choi Y, Karafillakis E, Perris A, Lin L, de Figueiredo A, Paterson P.   +5 more
europepmc   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

Research Progress of Universal Influenza Vaccine. [PDF]

Vaccines (Basel)
Wang L, Xie Q, Yu P, Zhang J, He C, Huang W, Wang Y, Zhao C.   +7 more
europepmc   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Impact of the Influenza Vaccine on Myocardial Infarction Risk: A Systematic Review. [PDF]

Cureus
Nagy S, Tehrani L, Abdool A, Israilov D, Denis O, Shin J, Asim F, Basharat K, Amini K, Kesselman MM.   +9 more
europepmc   +1 more source